Completed

A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

gemcitabine hydrochloride

+ carboplatin

+ dexamethasone

DrugBiological
Who is being recruted

Plasmablastic Lymphoma+56

+ Lymphadenopathy

+ Bacterial Infections and Mycoses

Over 18 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
Study Start: August 2003
See protocol details

Summary

Principal SponsorFred Hutchinson Cancer Center
Last updated: January 14, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: August 1, 2003

Actual date on which the first participant was enrolled.

OBJECTIVES: I. To determine the feasibility and safety of Gemcitabine/Carboplatin/Dexamethasone with or without Rituximab in previously treated lymphoid malignancies (rituximab will only be evaluated in CD20 positive malignancies). II. To determine the efficacy of the above regimen. III. To determine the ability to proceed to blood stem peripheral blood collection following the above regimens (the impact of above regimen on stem cell reserve). IV. To determine remission duration. All patients are treated with gemcitbine, carboplatin, and dexamethasone. Patients with CD20 + lymphomas also receive rituximab. After completion of study treatment, patients are followed up at 3-4 weeks and then every 6 months for 5 years.

Official TitleA Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies 
NCT00072514
Principal SponsorFred Hutchinson Cancer Center
Last updated: January 14, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

55 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Plasmablastic LymphomaLymphadenopathyBacterial Infections and MycosesBlood Protein DisordersBurkitt LymphomaCardiovascular DiseasesChronic DiseaseDNA Virus InfectionsEye NeoplasmsHematologic DiseasesHemorrhagic DisordersHerpesviridae InfectionsHodgkin DiseaseImmunoblastic LymphadenopathyImmune System DiseasesImmunoproliferative DisordersInfectionsLeukemiaLeukemia, LymphoidLymphatic DiseasesLymphomaLymphoma, FollicularLymphoma, Non-HodgkinLymphomatoid GranulomatosisLymphoproliferative DisordersWaldenstrom MacroglobulinemiaMycosesMycosis FungoidesNeoplasmsNeoplasms by Histologic TypeNeoplasms by SiteParaproteinemiasPathologic ProcessesPrecancerous ConditionsRecurrenceSezary SyndromeTumor Virus InfectionsVascular DiseasesVirus DiseasesLeukemia, B-CellLeukemia, Lymphocytic, Chronic, B-CellLeukemia, T-CellLeukemia-Lymphoma, Adult T-CellLymphoma, B-CellLymphoma, T-CellLymphoma, Large-Cell, ImmunoblasticLymphoma, Large B-Cell, DiffuseLymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, AnaplasticLymphoma, B-Cell, Marginal ZoneEpstein-Barr Virus InfectionsHemostatic DisordersLymphoma, Mantle-CellDisease AttributesPrecursor Cell Lymphoblastic Leukemia-LymphomaNeoplasms, Plasma CellLymphoma, Extranodal NK-T-CellIntraocular Lymphoma

Criteria

Inclusion Criteria: * Patients must have relapsed or primary refractory lymphoid malignancy (including B-cell, T-cell, or Hodgkin's Disease) * Revised European American classification (REAL), or World Health Organization (WHO) classification of patients malignancies must be provided * Patients must have measurable disease defined as lesions that can be accurately measured in two dimensions by computed tomography (CT), magnetic resonance imaging (MRI), medical photograph (skin or oral lesion), plain x-ray, or other conventional technique and a greatest transverse diameter of 1 cm or greater; or palpable lesions with both diameters \>= 2 cm; Note: CT scans remain the standard for evaluation of nodal disease * Patients must have a bone marrow aspirate and biopsy within 28 days of enrollment and no intervening anticancer therapy * Patients must have a CT of chest, abdomen, and pelvis within 28 days of enrollment; patients with evidence of adenopathy in the neck must have a CT of neck * Patients should not have evidence active central nervous system lymphoma * Patients must have a Southwest Oncology Group (SWOG) performance status of 0, 1, or 2 * Patients should have absolute neutrophil count (ANC) \>= 1,500/uL; exception: patients with cytopenia thought to be due to disease in their bone marrow, that do not meet this criteria, may be enrolled on the protocol at the Study Chair's discretion * Patients should have platelets \>= 100,000/uL; exception: patients with cytopenia thought to be due to disease in their bone marrow, that do not meet this criteria, may be enrolled on the protocol at the Study Chair's discretion * Serum bilirubin less than 2 times the upper limit of normal * Serum creatinine less than 1.5 times the upper limit of normal and creatinine clearance greater than 50/ mL per minute * Patients must have serum lactate dehydrogenase (LDH) performed within 14 days prior to treatment * All patients must be informed of the investigational nature of this study and have given written consent in accordance with institutional and federal guidelines * Must anticipate that patient will complete at least 2 cycles of chemotherapy Exclusion Criteria: * Patients known to be human immunodeficiency virus (HIV) positive * Pregnant or nursing women; men or women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method * Patients with other prior malignancies except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, cervical cancer in situ, or other cancer from which the patient has been disease-free for 5 years or greater unless approved by the Principal Investigator (PI) * Patients that are refractory (i.e., not responded or progressed within 6 months) to a carboplatin or cisplatin-based regimen or a gemcitabine-based regimen * Patients with active hepatitis B virus (HBV) infection or hepatitis * Patients that have other medical conditions that would contraindicate treatment with aggressive chemotherapy

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1 and 8, carboplatin IV over 30-60 minutes on day 1, and dexamethasone orally (PO) on days 1-4. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with CD20-POSITIVE LYMPHOMAS also receive rituximab IV on day 8.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Seattle, United StatesSee the location
CompletedOne Study Center